Drug pipeline

A drug pipeline is the set of drug candidates that an individual pharmaceutical company[1] or the entire pharmaceutical industry collectively has under discovery or development at any given point in time.[2] The drug pipeline is also sometimes restricted to a particular drug class or extended to mean the process of discovering drugs (the research and development pipeline).[3] The R&D pipeline involves various phases that can broadly be grouped in 4 stages: discovery, pre-clinical, clinical trials and marketing (or post-approval). Pharmaceutical companies usually have a number of compounds in their pipelines at any given time.

The drug pipeline is an important indicator of the value and future prospects of a company. Usually the more compounds in the pipeline, and the more advanced stage that these are in the better. Other factors that are taken into account when assessing the value of a pipeline include the size of the target market of each drug, the market share that the drug is expected to capture and the risk that it will not be approved.

The cost of developing a new drug is astronomical – typically a drug costs many hundreds of millions and can reach 1 billion dollars over 15–17 years. Assessing this risk and filtering out, as early as possible, compounds that may not eventually get approved is essential to the pharmaceutical industry and involves checking the effectiveness of drugs as well as the likelihood of toxic events (Adverse event prediction).

References

  1. ↑ Pietersz G (2019). "Drug pipeline". Moneyterms. Archived from the original on 9 June 2020. a drugs pipeline consists of the drugs that a company has under development or is testing
  2. ↑ Schuhmacher A, Gassmann O, Hinder M (2016). "New Innovation Models in Pharmaceutical R&D". In Schuhmacher A, Hinder M, Gassmann O (eds.). Value Creation in the Pharmaceutical Industry: The Critical Path to Innovation. Wiley‐VCH Verlag GmbH & Co. KGaA. pp. 400–415. doi:10.1002/9783527693405.ch18. ISBN 978-3-527-33913-6. the global R&D pipeline, defined as the number of pipeline projects in the phases of preclinical testing to market launch ... individual pipeline size of companies
  3. ↑ Addonizio M (February 2005). "Re-Engineering the Drug Development Pipeline". Genetic Engineering and Biotechnology News. 25 (3): 66. Archived from the original on 11 October 2007.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.